Skip to main content
Novacyt logo

Novacyt — Investor Relations & Filings

Ticker · ALNOV ISIN · FR0010397232 LEI · 213800BWAC2BF295EG28 PA Manufacturing
Open in API
Filings indexed 1,101 across all filing types
Latest filing 2023-01-03 Declaration of Voting R…
Country FR France
Listing PA ALNOV

About Novacyt

https://novacyt.com/

Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services. The company's core activities include the design, development, manufacturing, and commercialization of in vitro and molecular diagnostic tests, with a specialization in real-time PCR (qPCR) kits and reagents. Novacyt's solutions are applied across various markets, including clinical diagnostics for human health, with a focus on infectious diseases and oncology, as well as animal health and food safety. The company also offers custom development services, contract manufacturing, and pharmaceutical research services such as whole genome sequencing.

Recent filings

Filing Released Lang Actions
Liquidity Agreement and Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is identified by the RNS Number header and the closing statement indicating it is provided by RNS, the news service of the London Stock Exchange. The content details a 'Liquidity Agreement Monthly Update' concerning share purchases/sales by a third party (Invest Securities) and provides the 'Total Voting Rights' figure. This type of routine, periodic operational/share structure update, especially when disseminated via RNS, fits best under the general 'Regulatory Filings' category, as it is not a core financial report (10-K, IR, ER) nor a specific announcement like a dividend (DIV) or director dealing (DIRS). It is a general regulatory announcement.
2023-01-03 English
Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote
Transaction in Own Shares Classification · 95% confidence The document is titled "Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote" (Monthly information on the liquidity contract and on the total number of voting rights). It details the activity of the liquidity provider (Invest Securities) during December 2022, including shares bought and sold, and reports the total number of voting rights as of December 31, 2022. This type of regular, periodic disclosure concerning share transactions (often related to buybacks or market making) and total share capital/voting rights is characteristic of specific regulatory updates, but it does not fit the primary definitions of 10-K, ER, or IR. It is a specific report on share capital/transactions. The closest fit among the provided codes is 'Transaction in Own Shares' (POS) or potentially 'Capital/Financing Update' (CAP). However, since the core content is the monthly report on the liquidity contract (which involves buying/selling shares) and the total share count, 'Transaction in Own Shares' (POS) is the most specific category for reporting on share repurchase/issuance activities, even if executed by a third party under contract. Given the focus on the liquidity contract activity and the total share count, POS is the best fit, although 'RNS' (Regulatory Filings) is a possibility if this specific monthly report format isn't explicitly covered elsewhere. Since the content directly relates to share transactions (buying/selling shares under the liquidity contract), POS is selected.
2023-01-03 French
Non-Executive Director Change
Board/Management Information Classification · 99% confidence The document is a formal announcement disseminated via RNS (RNS Number : 8793I) concerning the retirement of a Non-Executive Director (Edwin Snape) effective December 31, 2022. This type of announcement, detailing changes in the company's board of directors or senior management, directly corresponds to the definition of 'Board/Management Information'. Therefore, the appropriate filing code is MANG.
2022-12-07 English
Approval of genesig COVID-19 3G PCR test in UK
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 6734I' and concludes with information about RNS, the news service of the London Stock Exchange. This strongly indicates a regulatory news service announcement. The content details the approval of a specific product (genesig® COVID-19 3G PCR test) under UK CTDA legislation. This type of specific, time-sensitive operational update that is disseminated via an official news wire service (RNS) and does not fit neatly into the defined financial report categories (like 10-K, IR, ER) is best classified as a general Regulatory Filing (RNS). Although it is a specific announcement, RNS serves as the appropriate fallback for non-standard regulatory disclosures disseminated through this channel.
2022-12-06 English
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release from Novacyt S.A. announcing that its genesig® COVID-19 3G PCR test has been approved in the UK under the CTDA legislation. This is a specific operational update regarding product regulatory status, not a comprehensive financial report (like 10-K or IR), a management change (MANG), or a general earnings announcement (ER). It is a specific regulatory/operational announcement. Since there is no specific category for 'Product Regulatory Approval', and it is not a general regulatory filing (RNS) or a legal proceeding (LTR), I must evaluate the closest fit. The content is highly specific to a product's regulatory clearance. Given the options, this type of announcement often falls under general Regulatory Filings (RNS) if it doesn't fit elsewhere, or potentially a Capital/Financing Update (CAP) if it were related to fundraising, which it is not. However, the core subject is a regulatory clearance announcement. Since RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' and this is a specific regulatory milestone announcement, RNS is the most appropriate fallback classification.
2022-12-06 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release from Novacyt S.A. dated December 6, 2022, announcing the approval of its genesig® COVID-19 3G PCR test in the UK under the CTDA (Coronavirus Test Device Approvals) regulations. This announcement details a specific regulatory/product update concerning diagnostic devices, rather than a general financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since the core subject is a regulatory approval for a specific product line under a specific regulatory framework (CTDA), it fits best under the general 'Regulatory Filings' category (RNS) as it is a specific, non-financial regulatory announcement that doesn't match the other specialized codes. Although it relates to a product, it is framed as an official announcement of regulatory status.
2022-12-06 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.